Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2025)
34 slides from Vita Life Sciences's shareholder meeting presentation, May 22, 2025
Slide 1: 2025 AGM Address & Presentation announcement
22 May 2025 Market Announcements Australian Securities Exchange Ltd 20 Bridge Street Sydney, NSW 2000 For personal use only Dear Sir/ Madam, 2025 ANNUAL GENERAL MEETING (AGM)-ADDRESS & PRESENTATION The Vita Life Sciences Ltd addresses to the 2025 AGM by the Chairman and the Managing Director, with r
Slide 2: Chairman's Script - Welcome and Introduction
Vita Life Sciences Limited – 2025 Annual General Meeting Chairman’s Script - 22 May 2025 Welcome Good morning ladies and gentlemen. I’m Henry Townsing, the Chairman of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today. Welcome to the VLS 2025 Annual General Meeting. We
Slide 3: Meeting Procedure and Agenda
I would like to welcome those shareholders that are observing us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please start by typing which resolution it relates to so that
Slide 4: Proxies and Financial Statements
Shareholders observing online who have already submitted their votes by proxy should note that your votes will already be counted towards the poll. The proxies have been inspected and all those validly lodged have been accepted. Proxies have been received representing up to 35,534,677 Shares or arou
Slide 5: Remuneration Report
Remuneration Report In accordance with the Notice of Meeting, I now move onto item 2, Resolution 1 which is as follows: To consider and, if thought fit, to pass, with or without amendment, Resolution 1, Adoption of the Remuneration Report for the Financial year ended 31 December 2024, as an ordinary
Slide 6: Re-election of Director and NED Remuneration
“That Henry Townsing, a director retiring by rotation in accordance with clause 14.4 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company.” An explanation of Resolution 2 and information on Mr. Townsing is found on page 10 of the Notice of the M
Slide 7: Resolution 4: Share Buy-Back
If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A. [PAUSE AND TAKE QUESTIONS] Members of the Company’s Board of Directors and their closely related parties are reminded that they may not vote on this resolution. If there are no
Slide 8: Poll Voting Procedure
[PAUSE AND TAKE QUESTIONS] Ladies and gentlemen, that concludes the resolutions to be voted. As mentioned, we are conducting a Poll on all resolutions. For this purpose, I appoint Mathew Hunter of Automic Registry Services shall be the Returning Officer. When you registered your attendance, voting s
Slide 9: Meeting Close
[PAUSE AND TAKE QUESTIONS] MEETING CLOSE There being no further questions or matters for discussion, I’d like to thank all shareholders for their attendance and will now end the today’s meeting. I declare the meeting closed. For personal use only 8
Slide 10: Address by the Managing Director
Vita Life Sciences Limited – 2025 Annual General Meeting Address by the Managing Director – 22nd May 2025 Opening remarks Good morning and a warm welcome to all shareholders, VLS directors and the Executive Team. Thank you for joining the Company’s Annual General Meeting. It is my pleasure to provid
Slide 11: Brand Positioning - Herbs of Gold and VitaHealth
I would like to now like to introduce you to Melissa Pereira – Group Head of Marketing who will provide an updated positioning of our brands. Melissa Pereira – Head of Marketing Thank you, Andrew. Today I’ll take just a few minutes to give you a high-level overview of two key brands in our portfolio
Slide 12: 2024 Product Launches and Awards
In 2024, we saw the launch of a new range in Malaysia, VitaHealth V-Style. Exclusive distribution to Watsons, the range includes 4 products in the fitness and post-workout space. The range was launched to meet the growing consumer demand – Euromonitor 2024 Malaysia report highlights sport nutrition
Slide 13: Annual General Meeting May 2025
For personal use only Annual General Meeting 22 May 2025
Slide 14: For personal use only
For personal use only 2. ANNUAL GENERAL MEETING 2025
Slide 15: For personal use only
For personal use only 3. ANNUAL GENERAL MEETING 2025
Slide 16: For personal use only
For personal use only 4. ANNUAL GENERAL MEETING 2025
Slide 17: For personal use only
For personal use only 5. ANNUAL GENERAL MEETING 2025
Slide 18: For personal use only
For personal use only 6. ANNUAL GENERAL MEETING 2025
Slide 19: For personal use only
For personal use only 7. ANNUAL GENERAL MEETING 2025
Slide 20: For personal use only
For personal use only 8. ANNUAL GENERAL MEETING 2025
Slide 21: For personal use only
For personal use only 9. ANNUAL GENERAL MEETING 2025
Slide 22: For personal use only
For personal use only 10. ANNUAL GENERAL MEETING 2025
Slide 23: For personal use only
For personal use only 11. ANNUAL GENERAL MEETING 2025
Slide 24: For personal use only
For personal use only 12.. ANNUAL GENERAL MEETING 2025
Slide 25: For personal use only
For personal use only 13. ANNUAL GENERAL MEETING 2025
Slide 26: For personal use only
For personal use only 14. ANNUAL GENERAL MEETING 2025
Slide 27: For personal use only
For personal use only 15. ANNUAL GENERAL MEETING 2025
Slide 28: For personal use only
For personal use only 16. ANNUAL GENERAL MEETING 2025
Slide 29: Resolutions
For personal use only Resolutions 1. Remuneration Report 2. Re-election of Director – Mr Henry Townsing 3. Aggregate Annual Remuneration Payable to Non-Executive Directors to be increased to a maximum of $300,000 from Year 2026 4. Share buy back 17. ANNUAL GENERAL MEETING 2025
Slide 30: Proxy-Resolution: Remuneration Report
Proxy-Resolution 1 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 1 Adoption of the Remuneration Report 19,724,424 85,222 6,298,540 8,608,643 18. ANNUAL GENERAL MEETING 2025
Slide 31: Proxy-Resolution: Re-election of Director
Proxy-Resolution 2 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Re-election of Director 2 29,183,993 48,144 6,298,540 - (Henry Townsing) 19. ANNUAL GENERAL MEETING 2025
Slide 32: Proxy-Resolution: Non-Executive Director Remuneration
Proxy-Resolution 3 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION Aggregate Annual Remuneration Payable 3 to Non-Executive Directors be increased 20,121,222 89,722 6,298,540 8,435,693 to maximum of $300,000 from Year 2026 20. ANNUAL GENERAL MEETING 2025
Slide 33: Proxy-Resolution: Share Buy-back
Proxy-Resolution 4 For personal use only PROXY’S RESOLUTIONS IN FAVOUR AGAINST EXCLUDED DISCRETION 4 Share buy-back 13,279,794 32,843 22,222,040 - 21. ANNUAL GENERAL MEETING 2025
Slide 34: Disclaimer
Disclaimer For personal use only This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences or VLS) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of